eGFP/Luciferase BCMA Knockout RPMI-8226 Cell Line

Description

eGFP/Luciferase BCMA Knockout RPMI-8226 Cell Line is a dual-reporter human multiple myeloma model generated from RPMI-8226 cells through CRISPR/Cas9-mediated knockout of BCMA (B-cell maturation antigen), combined with stable integration of enhanced green fluorescent protein (eGFP) and luciferase reporters. This advanced design preserves plasma cell morphology and native myeloma markers (CD38, CD138), while providing complementary imaging capabilities—fluorescence for spatial localization and bioluminescence for quantitative tumor burden measurement. The BCMA-null background makes this line a critical isogenic control for BCMA-targeted therapies including CAR-T, bispecific antibodies, and antibody-drug conjugates, while enabling investigation of BCMA-independent resistance mechanisms. Suitable for in vitro assays and in vivo xenograft studies, the dual-reporter system facilitates real-time tracking of tumor dynamics, immune interactions, and therapeutic responses. Cryopreserved at low passage (<P20) for genetic stability and validated free of HIV-1, HBV, HCV, syphilis, mycoplasma, fungi, yeast, and bacteria.